Finance

Lists
Outlook: 25.6% bullish·16.3% bearish
Go to analysis
IONS:NASDAQ
Ionis Pharmaceuticals Inc
$29.10
+0.14%
(+0.040) 1D
Nov 16, 9:46:36 AM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for IONS...
Open
$29.90
High
$29.99
Low
$28.48
Mkt. cap
4.85B
Avg. vol.
3.98M
Volume
121.85K
52-wk high
$86.74
52-wk low
$27.25
EPS
-$3.33
Beta
0.43
Shares outstanding
166.54M
No. of employees
1K
Open
$29.90
High
$29.99
Low
$28.48
Mkt. cap
4.85B
Avg. vol.
3.98M
Volume
121.85K
52-wk high
$86.74
52-wk low
$27.25
EPS
-$3.33
Beta
0.43
Shares outstanding
166.54M
No. of employees
1K
News stories
From web sources and news partners
Profile
Ionis Pharmaceuticals, Inc. is a biotechnology company that specializes in discovering and developing antisense therapy, as well as RNA interference and CRISPR therapeutics. The company was founded in 1989 is based in Carlsbad, California. The company was previously known as Isis Pharmaceuticals until December 2015. Wikipedia
About Ionis Pharmaceuticals Inc
CEOBrett P. Monia Ph.D.
Employees1.48K
Founded1989
HeadquartersCarlsbad, California, United States
SectorHealth Care
IndustryBiotechnology
Websiteionis.com
Analyst ratings
Based on 19 analysts giving stock ratings to IONS in the past 3 months
Strong buy
Buy
18
Hold
1
Sell
0
12-month forecast
Based on 19 Wall Street analysts offering 12 month price targets for IONS in the last 3 months.
Highest
Current $29.10
$100.00 (+243.64%)
Average
$72.39 (+148.76%)
Lowest
$41.00 (+40.89%)
Analyst
Recommendation
Action
Price target
Projected
Date
David Lebowitz
BMO Capital
Buy
Maintained
$66.00
+126.8%
11/10/2026
Salveen Richter
Goldman Sachs
Hold
Reiterated
$41.00
+40.9%
11/09/2026
Justin Kim
Oppenheimer
Buy
Reiterated
$70.00
+140.5%
11/10/2026
Yaron Werber
TD Cowen
Buy
Maintained
$53.00
+82.1%
11/10/2026
Michael Ulz
Morgan Stanley
Buy
Reiterated
$75.00
+157.7%
11/10/2026
Joon Lee
UBS
Buy
Maintained
$81.00
+178.4%
11/09/2026
Gary Nachman
Canaccord Genuity
Buy
Maintained
$72.00
+147.4%
11/10/2026
Luca Issi
RBC Capital
Buy
Maintained
$60.00
+106.2%
11/09/2026
Eric Joseph
Citi
Buy
Maintained
$100.00
+243.6%
11/09/2026
Yanan Zhu
Wells Fargo
Buy
Reiterated
$80.00
+174.9%
11/10/2026
Jason Gerberry
Bank of America Securities
Buy
Reiterated
$63.00
+116.5%
11/09/2026
Eliana Merle
Barclays
Buy
Maintained
$70.00
+140.5%
11/11/2026
Allison Bratzel
Piper Sandler
Buy
Maintained
$87.00
+199%
11/09/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Maintained
$70.00
+140.5%
11/10/2026
Tiago Fauth
Raymond James
Buy
Maintained
$79.00
+171.5%
10/20/2026
Joseph Stringer
Needham
Buy
Maintained
$86.00
+195.5%
09/23/2026
Myles Minter
William Blair
Buy
Maintained
-
-
09/22/2026
Jessica Fye
J.P. Morgan
Buy
Reiterated
$70.00
+140.5%
09/22/2026
Debjit Chattopadhyay
Guggenheim
Buy
Maintained
$80.00
+174.9%
09/14/2026
Unknown Analyst
BMO Capital
Hold
Initiated
$60.00
+106.2%
08/19/2026
Unknown Analyst
Wells Fargo
Buy
Maintained
$95.00
+226.5%
08/14/2026
Paul Matteis
Stifel Nicolaus
Hold
Maintained
$68.00
+133.7%
08/02/2026
Andy Chen
Wolfe Research
Hold
Downgraded
-
-
07/15/2026
Akash Tewari
Jefferies
Buy
Maintained
$90.00
+209.3%
07/15/2026
Unknown Analyst
Guggenheim
Buy
Maintained
$106.00
+264.3%
06/05/2026
Unknown Analyst
Citi
Buy
Initiated
$115.00
+295.2%
05/15/2026
Unknown Analyst
Canaccord Genuity
Buy
Initiated
$110.00
+278%
04/20/2026
Unknown Analyst
Raymond James
Buy
Initiated
$104.00
+257.4%
04/10/2026
Last report
Nov 9, 2026
Fiscal period
Q3 2026
-$0.40 / -$0.93
+56.81%beat
Revenue / Est. (USD)
242.72M / 184.38M
+31.64%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
203.33M
246.09M
267.95M
242.72M
Cost of goods sold
309.20M
213.16M
208.75M
207.50M
Cost of revenue
309.20M
213.16M
208.75M
207.50M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
108.59M
150.36M
160.60M
164.72M
Operating expense
108.59M
150.36M
161.50M
165.92M
Total operating expenses
417.79M
363.52M
370.24M
373.42M
Operating income
-214.46M
-117.42M
-102.29M
-130.70M
Other non operating income
57.00K
-456.00K
987.00K
277.00K
EBT including unusual items
-227.92M
-92.31M
-113.38M
-110.11M
EBT excluding unusual items
-212.36M
-114.89M
-103.20M
-119.64M
Income tax expense
1.48M
218.00K
1.26M
-141.00K
Effective tax rate
-0.65%
-0.24%
-1.11%
0.13%
Other operating expenses
-
-
900.00K
1.20M
Net income
-229.39M
-92.53M
-114.65M
-109.97M
Net profit margin
-112.82%
-37.60%
-42.79%
-45.31%
Earnings per share
-1.15
-0.30
-0.42
-0.40
Interest and investment income
24.73M
25.48M
20.23M
19.54M
Interest expense
-22.69M
-22.50M
-22.12M
-8.76M
Net interest expenses
2.04M
2.99M
-1.89M
10.79M
Depreciation and amortization charges
-
-
-
-
EBITDA
-210.56M
-113.46M
-98.16M
-126.37M
Gain or loss from assets sale
638.00K
40.00K
441.00K
815.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps